20Dec/18
Regeneron’s Lymphoma Bispecific Antibody Drug Achieved 100% Overall Response Rate
In the 2018 American Society of Hematology (ASH) annual meeting, Regeneron, the US biopharmaceutical company, announced new data from Phase I proof-of-concept studies on the bispecific antibody REGN1979 for the treatment ofRead More…